NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
NYU Langone Health
Children's Oncology Group
Barbara Ann Karmanos Cancer Institute